Literature DB >> 25348523

An optimized mouse thigh infection model for enterococci and its impact on antimicrobial pharmacodynamics.

Carlos A Rodriguez1, Maria Agudelo2, Javier M Gonzalez2, Omar Vesga3, Andres F Zuluaga4.   

Abstract

Negligible in vivo growth of enterococci and high-level dispersion of data have led to inaccurate estimations of antibiotic pharmacodynamics (PD). Here we improved an in vivo model apt for PD studies by optimizing the in vitro culture conditions for enterococci. The PD of vancomycin (VAN), ampicillin-sulbactam (SAM), and piperacillin-tazobactam (TZP) against enterococci were determined in vivo, comparing the following different conditions of inoculum preparation: aerobiosis, aerobiosis plus mucin, and anaerobiosis plus mucin. Drug exposure was expressed as the ratio of the area under the concentration-time curve for the free, unbound fraction of the drug to the MIC (fAUC/MIC) (VAN) or the time in a 24-h period that the drug concentration for the free, unbound fraction exceeded the MIC under steady-state pharmacokinetic conditions (fT(>MIC)) (SAM and TZP) and linked to the change in log10 CFU/thigh. Only anaerobiosis plus mucin enhanced the in vivo growth, yielding significant PD parameters with all antibiotics. In conclusion, robust in vivo growth of enterococci was crucial for better determining the PD of tested antibacterial agents, and this was achieved by optimizing the procedure for preparing the inoculum.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25348523      PMCID: PMC4291355          DOI: 10.1128/AAC.02352-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Identification of aerobically and anaerobically induced genes in Enterococcus faecalis by random arbitrarily primed PCR.

Authors:  B D Shepard; M S Gilmore
Journal:  Appl Environ Microbiol       Date:  1999-04       Impact factor: 4.792

2.  The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.

Authors:  Arnold Louie; Caroline Grasso; Nadzeya Bahniuk; Brian Van Scoy; David L Brown; Robert Kulawy; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

3.  In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.

Authors:  Catharine C Bulik; Pamela R Tessier; Rebecca A Keel; Christina A Sutherland; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

4.  Modeling of the bacterial growth curve.

Authors:  M H Zwietering; I Jongenburger; F M Rombouts; K van 't Riet
Journal:  Appl Environ Microbiol       Date:  1990-06       Impact factor: 4.792

5.  Cytolysin gene expression in Enterococcus faecalis is regulated in response to aerobiosis conditions.

Authors:  A M Day; J H Cove; M K Phillips-Jones
Journal:  Mol Genet Genomics       Date:  2003-02-22       Impact factor: 3.291

6.  Vancomycin-resistant Enterococci may obtain nutritional support by scavenging carbohydrate fragments generated during mucin degradation by the anaerobic microbiota of the colon.

Authors:  Nicole J Pultz; Lansing C Hoskins; Curtis J Donskey
Journal:  Microb Drug Resist       Date:  2006       Impact factor: 3.431

7.  Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.

Authors:  Prachi K Dandekar; Pamela R Tessier; Peter Williams; Charlie H Nightingale; David P Nicolau
Journal:  J Antimicrob Chemother       Date:  2003-08-13       Impact factor: 5.790

8.  Evaluation of antimicrobial agents in the rabbit model of endocarditis.

Authors:  M A Sande
Journal:  Rev Infect Dis       Date:  1981 Nov-Dec

Review 9.  The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.

Authors:  J M Hyatt; P S McKinnon; G S Zimmer; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

Review 10.  Structure, function, and biology of the Enterococcus faecalis cytolysin.

Authors:  Daria Van Tyne; Melissa J Martin; Michael S Gilmore
Journal:  Toxins (Basel)       Date:  2013-04-29       Impact factor: 4.546

View more
  5 in total

1.  A strain-independent method to induce progressive and lethal pneumococcal pneumonia in neutropenic mice.

Authors:  Andres F Zuluaga; Beatriz E Salazar; Maria Agudelo; Carlos A Rodriguez; Omar Vesga
Journal:  J Biomed Sci       Date:  2015-03-25       Impact factor: 8.410

2.  Establishment of Experimental Murine Peritonitis Model with Hog Gastric Mucin for Carbapenem-Resistant Gram-Negative Bacteria.

Authors:  Jung Yeon Park; Chulmin Park; Hye Sun Chun; Ji Hyun Byun; Sung Yeon Cho; Dong Gun Lee
Journal:  Infect Chemother       Date:  2017-03-06

3.  A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone.

Authors:  Ivone Jimenez-Toro; Carlos A Rodriguez; Andres F Zuluaga; Julian D Otalvaro; Omar Vesga
Journal:  PLoS One       Date:  2020-12-08       Impact factor: 3.240

4.  Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam.

Authors:  Carlos A Rodriguez; Maria Agudelo; Yudy A Aguilar; Andres F Zuluaga; Omar Vesga
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

5.  Comparison of In Vivo Pharmacokinetics and Pharmacodynamics of Vancomycin Products Available in Korea.

Authors:  Hee Kyung Kim; Su Mi Choi; Gaeun Kang; Kyung Hwa Park; Dong Gun Lee; Wan Beom Park; Su Jin Rhee; SeungHwan Lee; Sook In Jung; Hee Chang Jang
Journal:  Yonsei Med J       Date:  2020-04       Impact factor: 2.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.